Fully human antagonistic antibodies targeting FPR2 through dual extracellular-loop engagement for gastric cancer therapy
Antibody Therapeutics · 29.06.2026 · 9 (3) · 449-459
DOI: 10.1093/abt/tbag035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 03.07.2026. Verfasst von Min Su Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmaceutical Chemistry, Kookmin University, Seoul, 02707, Republic of Korea. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bio&Medical Technology Development Program, National Research Foundation, Korean government.
Abstract (Originalsprache)
Background
Gastric cancer (GC) remains a major cause of cancer mortality worldwide, particularly in metastatic stages. N-formyl peptide receptor 2 (FPR2), a class A G protein-coupled receptor activated by the Helicobacter pylori–derived peptide Hp(2–20), promotes GC progression by stimulating oncogenic signaling pathways. However, no clinically applicable agents selectively targeting FPR2 have been developed.
Methods
We generated fully human antagonistic antibodies targeting FPR2 using a two-step discovery strategy. A CDR-H3–focused synthetic single-chain variable fragment library was screened against an extracellular loop 3 (ECL3) peptide, followed by light-chain engineering to confer dual engagement of extracellular loop 2 (ECL2).
Results
The engineered antibody exhibited dose-dependent binding to both ECL2 and ECL3 peptides, selectively recognized FPR2 over other FPR family members, and showed nanomolar binding to FPR2-expressing cancer cells. The antibody inhibited Hp(2–20)–induced calcium mobilization and suppressed migration and invasion of Adenocarcinoma Gastric (AGS) gastric cancer cells. Structural modeling indicated a lid-like binding mode occluding the orthosteric pocket.
Conclusions
We developed a fully human antagonistic antibody that selectively binds and inhibits FPR2 through dual extracellular-loop engagement. The antibody potentially suppresses FPR2-driven signaling and invasive behaviors in gastric cancer cells, supporting its development for therapeutic application. Further assessment of its efficacy in vivo is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biopharmaceutical Chemistry, Kookmin University, Seoul, 02707, Republic of Korea.
- Antibody Research Institute, Kookmin University, Seoul, 02707, Republic of Korea.
- Biopharmaceutical Chemistry Major School of Applied Chemistry, Kookmin University, Seoul, 02707, Republic of Korea.
- Department of Pharmaceutical Engineering, Kookmin University, Seoul, 02707, Republic of Korea.
ORCID-Profile: Min Su Kim, Tae Hyun Kang
Förderung
- Bio&Medical Technology Development Program
- National Research Foundation
- Korean government
Zitieren
APA
Kim, M. S., & Kang, T. H. (2026). Fully human antagonistic antibodies targeting FPR2 through dual extracellular-loop engagement for gastric cancer therapy. Antibody Therapeutics, 9(3), 449-459. https://doi.org/10.1093/abt/tbag035
Vancouver
Kim MS, Kang TH. Fully human antagonistic antibodies targeting FPR2 through dual extracellular-loop engagement for gastric cancer therapy. Antibody Therapeutics. 2026;9(3):449-459. doi:10.1093/abt/tbag035
BibTeX
@article{Kim2026,
author = {Kim, Min Su and Kang, Tae Hyun},
title = {Fully human antagonistic antibodies targeting FPR2 through dual extracellular-loop engagement for gastric cancer therapy},
journal = {Antibody Therapeutics},
year = {2026},
volume = {9},
number = {3},
pages = {449--459},
doi = {10.1093/abt/tbag035}
}
EUVIMED